Recursion Pharmaceuticals, Inc. RXRX Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported increase (decrease) in contract liabilities and current deferred income of -$2.25M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income increased by 77.0% year-over-year, from -$9.76M to -$2.25M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 2 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a 91.8% compound annual growth rate (CAGR), from -$10M to -$36.77M.